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Type 2 diabetes is an increasingly common, serious metabolic disorder with a substantial inherited component. It is
characterised by defects in both insulin secretion and action. Progress in identification of specific genetic variants
predisposing to the disease has been limited. To complement ongoing positional cloning efforts, we have undertaken a
large-scale candidate gene association study. We examined 152 SNPs in 71 candidate genes for association with
diabetes status and related phenotypes in 2,134 Caucasians in a case-control study and an independent quantitative
trait (QT) cohort in the United Kingdom. Polymorphisms in five of 15 genes (33%) encoding molecules known to
primarily influence pancreatic b-cell function—ABCC8 (sulphonylurea receptor), KCNJ11 (KIR6.2), SLC2A2 (GLUT2),
HNF4A (HNF4a), and INS (insulin)—significantly altered disease risk, and in three genes, the risk allele, haplotype, or
both had a biologically consistent effect on a relevant physiological trait in the QT study. We examined 35 genes
predicted to have their major influence on insulin action, and three (9%)—INSR, PIK3R1, and SOS1—showed significant
associations with diabetes. These results confirm the genetic complexity of Type 2 diabetes and provide evidence that
common variants in genes influencing pancreatic b-cell function may make a significant contribution to the inherited
component of this disease. This study additionally demonstrates that the systematic examination of panels of
biological candidate genes in large, well-characterised populations can be an effective complement to positional
cloning approaches. The absence of large single-gene effects and the detection of multiple small effects accentuate the
need for the study of larger populations in order to reliably identify the size of effect we now expect for complex
diseases.
Introduction
Type 2 diabetes is a serious metabolic disease associated
with an increased risk of premature death and substantial
disability, largely mediated through its adverse effects on the
vasculature. The prevalence of the disease is increasing, and
the World Health Organisation estimates suggest that by 2025
there will be 300 million affected individuals worldwide (King
et al. 1998). The disorder is characterised by a combination of
impaired insulin secretion and insulin action, both of which
precede and predict the onset of disease (Weyer et al. 1999).
Through its adverse impact on insulin action, obesity is a
major risk factor for the disease. Although environmental
factors, both post- and prenatal, play an important role in
determining the risk of disease, a substantial body of evidence
supports the notion that disease susceptibility is inﬂuenced
by inherited factors (Zimmet 1982). While the molecular basis
for several uncommon Mendelian forms of Type 2 diabetes
have been deﬁned (Vionnet et al. 1992; Yamagata et al. 1996a,
1996b; Horikawa et al. 1997; Stoffers et al. 1997; Barroso et al.
1999; Malecki et al. 1999; Savage et al. 2002), the nature and
range of allelic variants conferring susceptibility to the more
common forms of this disorder remain poorly deﬁned. Many
investigators have embarked on attempts to identify diabetes
susceptibility genes through genome-wide linkage-based
approaches using multigenerational pedigrees and/or large
numbers of affected sibpairs. Regions of signiﬁcant linkage,
some of which have been replicated in more than one study,
have been identiﬁed. To date, however, only Calpain 10
(CAPN10; LocusLink ID 11132) has emerged from such studies
as a new putative diabetogene (Horikawa et al. 2000). While
some subsequent studies have supported a role for the
CAPN10 alleles originally described as susceptibility alleles,
others have found associations with different alleles and some
have found no association with this gene (Baier et al. 2000;
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The positional cloning effort has been supplemented by a
large number of studies examining speciﬁc candidate genes
using a variety of methodologies, mostly of the case-control
association design. Although many positive reports have
emerged, few have been consistently replicated. Of these
candidates, the most compelling evidence to date, generated
from a meta-analysis of multiple published studies, is that a
common amino acid variant in the N-terminus of the nuclear
receptor peroxisome proliferator-activated receptor c
(PPARG; LocusLink ID 5468) confers signiﬁcant protection
against the development of Type 2 diabetes (Altshuler et al.
2000). More recently, evidence has accumulated supporting a
role for the E23K variant of KCNJ11 (LocusLink ID 3767) in
Type 2 diabetes predisposition (Hani et al. 1998; Gloyn et al.
2001, 2003; Love-Gregory et al. 2003; Nielsen et al. 2003).
Whole-genome association studies in large case-control
populations may ultimately have the greatest power to detect
alleles of small but signiﬁcant effects on the susceptibility to
common diseases such as Type 2 diabetes. As yet, however,
the resource implications of such an approach are prohib-
itive. In the meantime, knowledge of both mammalian
biology and disease pathogenesis is progressing rapidly, and
it is possible to identify a large panel of known genes, the
dysfunction of which might reasonably be considered likely to
contribute to Type 2 diabetes. In this study we have identiﬁed
152 informative single nucleotide polymorphisms (SNPs) in
71 such genes and, using these, have examined their
association with Type 2 diabetes and related intermediate
phenotypes in Caucasian subjects from the United Kingdom.
Results/Discussion
Overall Study Design
Candidate gene studies are based on selection of genes with
a known or inferred biological function whose role makes it
plausible that they may predispose to disease or the observed
phenotype. These types of studies are similar to traditional
epidemiological approaches in which an a priori hypothesis
between exposure to a given factor (in this case, a genotype at
a given locus) and disease is formulated. To date, most Type 2
diabetes candidate gene studies have largely lacked thorough-
ness and sensitivity, as they have tested a limited number of
genes and variants in small populations or in populations that
were poorly matched or phenotyped, frequently resulting in a
lack of replication of the weak associations detected
(Altshuler et al. 2000). Our strategy aimed to address these
problems by a unique combination of features, including
comprehensive SNP discovery in a large number of candidate
genes, testing of a large number of SNPs, use of two
independent populations, and analysis of haplotypes in
addition to individual SNPs where possible.
Figure 1 illustrates the overall design of the study. On the
basis of their known or putative role in glucose metabolism,
71 candidate genes were selected for study (Table 1). These
were subdivided into three broad groups: (1) genes primarily
involved in pancreatic b-cell function; (2) genes primarily
inﬂuencing insulin action and glucose metabolism in the
main target tissues, muscle, liver, and fat; and (3) other genes.
This group includes genes that inﬂuence processes poten-
tially relevant to diabetes, such as energy intake, energy
expenditure, and lipid metabolism. A de novo search for
common SNPs was undertaken using ﬂuorescent single-
stranded conformation polymorphism (fSSCP) examination
of all coding regions and splice junctions in a variety of
human populations. All genes were minimally screened
against 47 samples of mixed ethnicity, providing 0.99
probability of detecting variants with a minor allele fre-
quency of 0.05. Our ‘in-house’ polymorphism detection
programme identiﬁed 954 SNPs in the 71 genes, with a range
of allele frequencies from 0.003 to 0.50. Of the 152 SNPs
chosen for further study (Table S1, found at http://dx.doi.org/
10.1371/journal.pbio.0000020.st001), the great majority had a
minor allele frequency of greater than 5%, but in a few
instances less frequent variants were typed when the
candidate gene had strong biological plausibility and there
were no known polymorphisms of higher frequency at the
time of SNP selection.
The 152 SNPs were genotyped in a population-based
cohort of 517 unrelated Caucasians in the United Kingdom
with Type 2 diabetes and an equal number of controls with
normal glycated haemoglobin (HbA1c) levels, individually
matched to cases by age, sex, and geographical location. A
second independent population was also genotyped for the
same 152 SNPs. This consisted of 1,100 middle-aged
Caucasian subjects in the United Kingdom who had been
extensively and serially phenotyped for glucose tolerance and
variables related to insulin secretion, insulin action, and
adiposity. In the ﬁrst stage of data analysis, all SNPs (and
haplotypes when multiple SNPs were present at the same
gene) were examined for their association with diabetes in the
case-control study using multiple models of inheritance. In
the second phase of analysis, all SNPs and haplotypes showing
statistically signiﬁcant association with diabetes status in the
ﬁrst phase were examined for association with glucose levels
and other intermediate phenotypes in the quantitative trait
Figure 1. Study Design
Candidate genes were selected based on known or putative function.
A de novo polymorphism discovery step was undertaken to identify
novel variants for association studies. We selected 152 SNPs and
tested them in a case-control study and a QT study. Association
analysis with Type 2 diabetes was done for SNPs and haplotypes
under multiple genetic models. Only SNPs and haplotypes associated
with disease were evaluated for association with ﬁve diabetes-related
QTs under the same model in the QT study.
DOI: 10.1371/journal.pbio.0000020.g001
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Type 2 Diabetes GenesTable 1. Genes with SNPs Genotyped in This Study
Group Subgroup Ofﬁcial
Gene
Symbol
Common Symbol Number of
SNPs
Tested in
This Study
Pancreatic b-cell function CDX2 CDX3 1
NEUROD1 1
PAX4 1
PAX6 1
HNF4A 3
TCF1 HNF1A 1
TCF2 HNF1B 2
ABCC8 SUR1 16
ADCYAP1R1 PACAPR 1
CPE 2
GCK 1
GLP1R 5
INS 1
KCNJ11 KIR6.2 4
SLC2A2 GLUT2 6
Insulin action INSR signalling pathway AKT1 PKB 1
AKT2 1
CAV3 1
FOXO3A FKHRL1 1
FYN 1
GRB10 1
GRB14 2
GRB2 1
GRB7 1
INSR IR 7
IRS1 2
PDE3B 1
PIK3CA 1
PIK3R1 p85a 3
RPS6KA2 1
SLC2A4 GLUT4 2
SOS1 2
SOS2 2
Negative regulator of insulin action AHSG 1
ENPP1 PC-1 2
GH1 1
INPPL1 SHIP2 1
Carbohydrate metabolism FBP1 2
GPD1 1
HK1 2
HK2 4
PFKM 1
SLC2A5 GLUT5 1
G6PT1 1
GYS1 1
GYS2 1
PPP1CC 1
PPP1R3A 3
PPP2R1A 1
PCK1 PEPCK 11
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Type 2 Diabetes Genes(QT) study population. The intermediate phenotypes chosen
for study were fasting and 2-h post-glucose load plasma
glucose levels (measures of glucose tolerance), fasting insulin
(a measure of insulin sensitivity), 30-min insulin incremental
response (a measure of b-cell function), and body mass index
(BMI) (a measure of adiposity).
Power to detect an association is dependent on several
factors: the frequency of the ‘predisposing’ allele, genotype,
or haplotype; the accepted false-positive or Type 1 error rate
(a); and the odds ratio (OR) or effect size. Rarer alleles,
genotypes, or haplotypes with small effects require larger
sample sizes to attain the same power to detect an association,
as compared to more frequent alleles or alleles with larger
effects. At the time that we collected the populations and
designed this study, our power calculations had shown that a
sample size of 500 cases and 500 matched controls would have
80% power to detected effect sizes as small as 1.3–1.7 OR,
depending on the frequency of the predisposing allele, with a
5% Type 1 error rate (Figure 2).
Overview of Results of Association Studies
Table S1 shows the genotype counts for all 152 SNPs in the
case-control and QT studies. In the control subjects, 16 SNPs
(10.6%) had a minor allele frequency below 5%; 19 (12.5%)
had a minor allele frequency between 5% and 10%; and 117
(76.9%) had a minor allele frequency greater than or equal to
10%. Each variant was tested for association with disease
status under several genetic models. Twenty SNPs in 11
different genes showed statistically signiﬁcant association
with disease status (p , 0.05) under at least one model (Table
2). The strongest statistical evidence for disease association
was for genes SOS1 (LocusLink ID 6654), SLC2A2 (LocusLink
ID 6514), PIK3R1 (LocusLink ID 5295), ABCC8 and KCNJ11
(LocusLink ID 6833), and INSR (LocusLink ID 3643). Of the
29 loci with multiple SNPs, only three—HNF4A (LocusLink ID
Table 1. Continued
Group Subgroup Ofﬁcial
Gene
Symbol
Common Symbol Number of
SNPs
Tested in
This Study
Others Lipid metabolism CETP 3
FABP2 1
FABP4 aP2 1
LIPC HL 3
LIPE HSL 1
PLCG1 1
PPARG 2
Feeding behaviour/energy homeostasis GAL GALN 1
PPARGC1 PGC1 4
ADRB3 1
PYY 1
Others USF1 1
KCNJ6 KIR3.2 1
STXBP3 UNC-18c 1
SGNE1 1
NCOA1 1
RXRG 2
ABCC9 SUR2 4
ENPP2 PDNP2 2
GC VDBP 4
NOS3 eNOS 4
Candidate genes, identified by official HUGO Gene Nomenclature Committee symbols, are grouped by known or putative biological function, with the number of genotyped
polymorphisms per gene shown.
DOI: 10.1371/journal.pbio.0000020.t001
Figure 2. Power Calculations
Power of the current Cambridgeshire Case-Control Study to detect
associations with risk allele of varying frequencies and with a Type 1
error rate of 5%. Abbreviations: p0, frequency of the predisposing
allele; chr, number of chromosomes. Graphs were plotted with the PS
power and sample-size program (available at http://www.mc.
vanderbilt.edu/prevmed/ps; DuPont and Plummer 1997).
DOI: 10.1371/journal.pbio.0000020.g002
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Type 2 Diabetes Genes3172) INSR, and ABCC8–KCNJ11—showed signiﬁcant associ-
ation of particular haplotypes with disease status (Figure 3;
T a b l e3 ) .I no n l yo n ec a s e( HNF4A) was a haplotype
signiﬁcantly associated with disease risk (see below) when
no signiﬁcant association was seen with any individual SNP in
that gene. Table S2, found at http://dx.doi.org/.1371/journal.
pbio.0000020.st002, shows the results of association studies
undertaken in the QT population, further examining the
SNPs that had shown signiﬁcant association in the case-
control study. Table 3 shows the relationship between
disease-associated haplotypes at ABCC8–KCNJ11, HNF4A,
and INSR with intermediate phenotypes in the QT study.
We now consider in more detail, the data for those genes
where the strongest and most consistent effects were seen.
Genes Primarily Affecting b-Cell Function
ABCC8 and KCNJ11 (encoding, respectively, the sulphony-
lurea receptor and inwardly rectifying potassium channel KIR
6.2). The genes encoding the two molecular components of
the voltage-gated potassium channel of the pancreatic b-cell
are located within 4.5 kb of each other on Chromosome 11.
KCNJ11 encodes the channel protein KIR6.2 and ABCC8
encodes an ATP-binding cassette (ABC) transporter-contain-
ing transmembrane protein (SUR1) that is thought to
regulate the activity of the channel and that also contains
the site to which sulphonylurea antidiabetic drugs bind.
Three SNPs in KCNJ11 were associated with disease under
multiple genetic models. The strongest statistical association
in this gene was with a 39-SNP (SNP74; OR 0.59, p ¼ 0.0027
under recessive model for allele 2) (see Table 2). In ABCC8,
ﬁve SNPs were associated with disease status under multiple
models; the strongest evidence for association with disease
were with SNP79 and SNP81, respectively an intronic variant
(OR 1.68, p ¼ 0.0043; see Table 2) and a missense variant
A1369S (OR 1.68, p¼0.0048; see Table 2). Although neither of
these two SNPs was signiﬁcantly associated with any trait in
the QT study, two other SNPs showed effects in the QT study
(see Table S2). SNP84 (IVS18–36) from ABCC8,w h i c h
associated with increased disease risk (OR 3.43, p ¼ 0.0163;
see Table 2) also associated with increased BMI (mean 28.2 kg/
m
2, 95% conﬁdence interval [CI] [26.6, 29.9] for homozygous
22 versus 26.2 kg/m
2, 95% CI [25.9, 26.5] for homozygous 11
and 26.3 kg/m
2, 95% CI [25.7, 26.8] for heterozygous subjects;
p ¼ 0.016) and associated with borderline signiﬁcance with
higher fasting glucose (5.53 mmol/l, 95% CI [5.29, 5.77] for
homozygous 22 versus 5.30 mmol/l, 95% CI [5.26, 5.35] for
homozygous 11 and 5.27 mmol/l, 95% CI [5. 19, 5.35] for
heterozygous subjects; p ¼ 0.057) under a recessive model for
allele 2 (see Table S2). SNP87 (K649), which was also
signiﬁcantly associated with increased disease risk (OR 3.90,
p ¼ 0.0157; see Table 2), also showed borderline signiﬁcant
association with decreased insulin secretion (23.6 pmol/mmol,
95% CI [18.6, 30.1] for homozygous 22 versus 29.8 pmol/
mmol, 95% CI [28.4, 31.1] for homozygous 11 and 30.9 pmol/
Table 2. Genes with Variants Significantly Associated with Type 2 Diabetes Status
Gene SNPID SNP Allele 2
Dominant
(22 þ 12)
Additive
Effect
Allele 2
Recessive
(11 þ 12)
OR p Value OR p Value OR p Value
SOS1 8 IVS17þ53 0.58 0.0032 0.58 0.0020
SLC2A2 21 IVS5–15 1.44 0.0117 1.35 0.0230
23 T198 1.39 0.0318 1.36 0.0323
24 T110I 1.49 0.0059 1.40 0.0114
PPARGC1 30 T528 0.83 0.0378
31 G482S 0.67 0.0295
PIK3R1 42 IVS4þ82 1.41 0.0090 1.34 0.0088
INS 72 3pþ92 . O 2 0.0258
KCNJ11 74 3pþ215 0.75 0.0299 0.76 0.0021 0.59 0.0027
76 A190 0.79 0.0127 0.62 0.0260
77 E23K 1.49 0.0333
ABCC8 79 IVS38þ54 1.25 0.0131 1.68 0.0043
81 A1369S 1.23 0.0256 1.68 0.0048
84 IVS18–36 3.43 0.0163
87 K649 3.90 0.0157
89 IVS11–74 2.82 0.0480
ABCC9 100 IVS13–76 1.99 0.0339
LIPC 114 IVS1þ49 0.76 0.0468 0.77 0.0291
PYY 123 IVS3þ68 1.47 0.0240 1.47 0.0157
INSR 131 IVS6þ43 1.48 0.0039 1.32 0.0119
SNP identifiers (SNPID), OR, significance level (p value), and genetic model are shown. p values for the additive effect are for the test for a linear trend across the genotypes,
which were coded as 0 ¼ 11, 1 ¼ 12, 2 ¼ 22. Allele 2 dominant refers to a combination of 12 þ 22 and allele 2 recessive refers to combination of 11 þ 12.
DOI: 10.1371/journal.pbio.0000020.t002
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Type 2 Diabetes Genesmmol, 95% CI [28.6, 33.4] for heterozygous subjects; p¼0.054;
see Table S2), consistent with a role for this gene in insulin
secretion. Given the close physical proximity of ABCC8 and
KCNJ11 and their role in the same functional unit, we
performed haplotype reconstructions with data from both
genes combined (see Figure 3A). Haplotype B was associated
with increased disease risk (OR 1.46, 95% CI [1.14, 1.85]; data
not shown), but did not show any signiﬁcant association in
the QT study (see Table 3).
Mutations in each of these genes have been associated with
familial persistent hyperinsulinaemia hypoglycaemia of in-
f a n c y( P H H I ) ,ar a r ed i s o r d e ro fg l u c o s eh o m e o s t a s i s
characterised by up-regulated insulin secretion despite severe
hypoglycaemia. In addition, evidence for association of
KCNJ11 DNA variants with Type 2 diabetes has been
evaluated in multiple studies, and until recently these data
have been conﬂicting. Several recent studies have, however,
suggested a role for the aminoacid variant E23K in Type 2
diabetes susceptibility (Hani et al. 1998; Gloyn et al. 2001,
2003; Schwanstecher and Schwanstecher 2002; Love-Gregory
et al. 2003; Nielsen et al. 2003). In total we tested four SNPs at
the KCNJ11 locus for association with disease status; of these,
three were tightly linked (data not shown) and all three had a
statistically signiﬁcant association with disease status (see
Table 2). In our study we replicated the effect of the E23K
polymorphism in Type 2 diabetes predisposition (KK
homozygous, OR 1.49, p ¼ 0.0333; see Table 2) with an OR
estimate in agreement with that demonstrated by the meta-
analysis of Nielsen et al. (2003); in addition, two other KCNJ11
SNPs associated with disease risk (SNP74 and SNP76). The
recent evidence from multiple studies and from meta-analysis
for association of the E23K SNP with Type 2 diabetes, along
with in vitro studies using cell lines expressing the E23K
mutation showing an increased stimulation threshold of
insulinsecretion (Schwanstecher et al. 2002), suggests that
E23K is the functional variant leading to increased disease
risk. Given our ﬁnding of high levels of linkage disequilibrium
(LD) between SNP74 and SNP76 with E23K (data not shown),
Figure 3. Genes with Haplotypes Associated with Type 2 Diabetes
Genomic organization with exons (black boxes or vertical lines) and with genotyped SNPs and SNPs utilised in the haplotype reconstructions (in
blue boxes) is shown. The most common haplotypes with population prevalence greater than 5% in the control population are shown, and the
measure of LD (r
2) is shown for a subset of the SNPs. (A) ABCC8–KCNJ11. (B) HNF4A. (C) INSR.
DOI: 10.1371/journal.pbio.0000020.g003
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Type 2 Diabetes Geneswe adjusted the measures of association at these sites for the
E23K genotype. These data suggest that these SNPs are
independently associated with diabetes (Table 4).
ABCC8 variants have been associated with Type 2 diabetes
in multiple studies (Inoue et al. 1996; T. Hansen et al. 1998;
Hart et al. 1999b). However, a recent large study failed to
replicate previous associations with Type 2 diabetes (Altshu-
ler et al. 2000). In our study we found evidence for association
with Type 2 diabetes in ﬁve of 16 ABCC8 SNPs tested. Owing
to the physical mapping of ABCC8 in close proximity to
Table 3. Association of ABCC8–KCNJ11, HNF4A, and INSR Haplotypes with Diabetes and QTs
ABCC8 SNP79, SNP82 Haplotype p Value
ABCD
Diabetes 1.00 1.46 (1.14, 1.85) 1.07 (0.80, 1.44) 0.94 (0.66, 1.34) 0.004
BMI 26.3 (26.0, 26.7) 26.0 (25.6, 26.4) 26.4 (25.9, 26.9) 26.0 (25.3, 26.7) 0.359
PG0 5.29 (5.24, 5.33) 5.26 (5.21, 5.31) 5.30 (5.23, 5.37) 5.24 (5.17, 5.32) 0.454
2hPG 5.88 (5.75, 6.02) 5.81 (5.68, 5.96) 5.91 (5.73, 6.09) 5.89 (5.66, 6.12) 0.810
INS0 41.8 (40.2, 43.5) 40.5 (38.4, 42.6) 40.8 (38.5, 43.3) 38.7 (36.0, 41.6) 0.253
Ins inc 30.3 (28.8, 31.8) 30.0 (28.4, 31.6) 30.3 (28.4, 32.4) 29.2 (27.2, 31.4) 0.818
HNF4A SNP138, SNP139 Haplotype p Value
ABC
Diabetes 1.00 0.83 (0.68, 1.00) 1.27 (0.95, 1.70) 0.017
BMI 26.2 (25.9, 26.5) 26.2 (25.8, 26.6) 26.3 (25.7, 27.0) 0.924
PG0 5.30 (5.25, 5.35) 5.23 (5.18, 5.28) 5.29 (5.20, 5.38) 0.089
2hPG 5.93 (5.81, 6.06) 5.74 (5.60, 5.89) 5.89 (5.60, 6.19) 0.072
INS0 40.9 (39.3, 42.5) 40.9 (38.8, 43.0) 42.8 (39.3, 46.6) 0.578
Ins inc 29.3 (28.0, 30.6) 31.5 (29.9, 33.3) 30.9 (28.1, 34.0) 0.028
INSR SNP130, SNP131, SNP132 Haplotype p Value
ABC
Diabetes 1.00 1.00 (0.80, 1.25) 1.34 (1.05, 1.71) 0.053
BMI 26.3 (25.9, 26.6) 26.3 (25.9, 26.7) 26.0 (25.6, 26.5) 0.522
PG0 5.27 (5.23, 5.32) 5.27 (5.21, 5.33) 5.32 (5.24, 5.39) 0.608
2hPG 5.87 (5.75, 5.99) 5.78 (5.61, 5.96) 6.00 (5.80, 6.20) 0.204
INS0 41.3 (39.6, 43.1) 40.4 (38.4, 42.5) 41.8 (39.2, 44.5) 0.621
Ins inc 30.2 (28.8, 31.6) 29.9 (28.1, 31.8) 30.7 (28.7, 32.8) 0.794
For case control, OR and 95% CI of haplotypes are shown. For QT, means and 95% CI of haplotypes are shown. Means were adjusted for age and sex, but not for BMI.
Abbreviations: BMI, body mass index (kg/m
2); PG0, fasting plasma glucose (mmol/l); 2hPG, 2-h plasma glucose (mmol/l); INS0, fasting insulin (pmol/l); Ins inc, 30-min insulin
increment (pmol/mmol). Associations significant at 0.10 and below are in italics bold, with association 0.05 or below in red bold.
DOI: 10.1371/journal.pbio.0000020.t003
Table 4. Association of KCNJ11 and ABCC8 Variants with Type 2 Diabetes Status Adjusted for E23K Genotype
Gene SNPID SNP Allele 2
Dominant
(22 þ 12)
Additive
Effect
Allele 2
Recessive
(11 þ 12)
OR p Value OR p Value OR p Value
KCNJ11 74 UTR3þ215 0.78 0.0846 0.78 0.0256 0.65 0.0149
76 A190 0.79 0.0948 0.82 0.0765 0.67 0.0672
ABCC8 79 IVS38þ54 1.62 0.3644 2.09 0.0652 3.67 0.0536
81 A1369S 1.36 0.5461 1.68 0.1878 2.85 0.1339
84 IVS18–36 0.99 0.9392 1.05 0.7251 3.23 0.0401
87 K649 1.09 0.5562 1.16 0.2767 4.36 0.0214
89 IVS11–74 0.83 0.1934 0.91 0.4635 3.16 0.0445
SNP identifiers (SNPID), OR, significance level (p value), and genetic model are shown. p Values for the additive effect are for the test for a linear trend across the genotypes,
which were coded as 0 ¼ 11, 1 ¼ 12, 2 ¼ 22. Allele 2 dominant refers to a combination of 12 þ 22 and the allele 2 recessive refers to combination of 11 þ 12.
DOI: 10.1371/journal.pbio.0000020.t004
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the ABCC8 locus could be completely explained through LD
between ABCC8 SNPs and the E23K variant at KCNJ11. After
adjustment for E23K, two ABCC8 SNPs (SNP79 and SNP81)
that were signiﬁcantly associated with diabetes (p ¼ 0.0043
and p ¼ 0.0048 for the recessive model; see Table 2) prior to
adjustment were no longer signiﬁcantly associated with
diabetes (p ¼ 0.0536 and p ¼ 0.1339 for the recessive model;
see Table 4). However, for the remaining three SNPs (SNP84,
SNP87, and SNP89), although the signiﬁcance levels were
reduced, they remained statistically signiﬁcant (p¼0.0401, p¼
0.0214, and p ¼ 0.0445 for the recessive model; see Table 4).
Moreover, the OR for two of these SNPs increased to 4.36 and
3.16, respectively. This suggests that there are effects at the
ABCC8 locus that are independent from the E23K KCNJ11
variant. The lowered signiﬁcance levels are likely due to loss
of power resulting from the adjustment. Our data and that
from at least nine other independent association and linkage
studies (T. Hansen et al. 2001) have shown some evidence for
ABCC8 involvement in Type 2 diabetes and related pheno-
types.
SLC2A2 (encoding GLUT2). SLC2A2 encodes the glucose
transporter GLUT2, a member of the facilitative glucose
transporter family that is highly expressed in pancreatic b-
cells and liver. We typed six SNPs in SLC2A2, three of which
(SNP21, SNP23, and SNP24) were signiﬁcantly associated with
diabetes status with an OR of approximately 1.4–1.5 (see
Table 2). The most highly signiﬁcant association was with a
T110I substitution (OR 1.49, p ¼ 0.0059) under a dominant
model for the minor allele. In the reduction process prior to
haplotype estimations (see Materials and Methods), only one
SNP (SNP21) contributed signiﬁcantly to disease association.
Therefore, haplotype reconstructions were not performed. In
the QT study, all three disease-associated SNPs were also
associated with lower levels of fasting plasma insulin. Rather
surprisingly allele 2 (A) at T198, which was associated with
increased disease risk, was associated with lower 2-h plasma
glucose. No other signiﬁcant associations with intermediate
phenotypes were seen.
Multiple previous studies have sought evidence for associ-
ation or linkage between SLC2A2 variants and Type 2
diabetes, and most have reported negative results. However,
all studies have been small and were insufﬁciently powered to
detect effects of modest size (Li et al. 1991; Baroni et al. 1992;
Tanizawa et al. 1994; Moller et al. 2001). SLC2A2 is a highly
plausible candidate gene for Type 2 diabetes, as it is a high Km
transporter that regulates entry of glucose into the pancreatic
b-cell, thus initiating the cascade of events leading to insulin
secretion. GLUT2 is also highly expressed in the liver, where
it is involved in the regulation of both glucose uptake and
output. It is notable that the alleles that associated with
increased diabetes risk were also all associated with lower
fasting insulin levels, suggesting that these may inﬂuence
basal insulin secretion. However, interpretation is complex,
as (1) fasting insulin is strongly inﬂuenced by insulin
sensitivity and (2) the potential risk alleles were not associated
with any impairment of insulin secretion in response to a
glucose load. Finally, allele 2 (A) at T198, which associated
with increased risk of diabetes in the case-control study, was
associated with lower 2-h glucose in the QT study. Clearly,
more detailed genetic mapping combined with functional
studies (which will be challenging in humans owing to the
inaccessibility of the pancreatic b-cell) will be needed to
identify the mechanism whereby variants in this gene
inﬂuence diabetes risk.
HNF4A (encoding hepatic nucleotide factor 4a). HNF4A (the
MODY1 gene) encodes an orphan hormone nuclear receptor
that, together with TCF1 (LocusLink ID 6927), encoding
HNF1a, TCF2 (LocusLink ID 6928), encoding HNF1b, and
FOXA2 (LocusLink ID 3170), encoding HNF3b, constitutes
part of a network of transcription factors controlling gene
expression in pancreatic b-cells, liver, and other tissues. In b-
cells, these transcription factors regulate expression of the
insulin gene as well as genes encoding proteins involved in
glucose transport and metabolism and in mitochondrial
metabolism, all of which are linked to insulin secretion
(Fajans et al. 2001). While no individual SNP in HNF4A was
signiﬁcantly associated with disease status, we identiﬁed a
haplotype (haplotype B in Figure 3B) that was signiﬁcantly
associated with reduced disease risk (OR 0.83, 95% CI [0.68,
1.00]; data not shown). In the QT study, this ‘reduced-risk’
haplotype was signiﬁcantly associated with increased insulin
secretion (mean¼31.5 pmol/mmol, 95% CI [29.9, 33.3] versus
29.3 pmol/mmol, 95% CI [28.0, 30.6] for haplotype A and 30.9
pmol/mmol, 95% CI [28.1, 34.0] for haplotype C]. Carriers of
this haplotype also showed a trend towards lower fasting and
2-h plasma glucose, compared to the subjects with the other
haplotypes (see Table 3). HNF4A maps to Chromosome 20
(Argyrokastritis et al. 1997) in a region that has been linked to
Type 2 diabetes in multiple studies (Bowden et al. 1997; Ji et
al. 1997; Zouali et al. 1997; Ghosh et al. 1999; Klupa et al. 2000;
Permutt et al. 2001). This positional information, combined
with the known role of major mutations at this gene in the
causation of autosomal-dominant maturity-onset diabetes of
the young (MODY), has led to HNF4A being considered as a
strong candidate for involvement in Type 2 diabetes.
However, most studies to date have failed to identify an
association between variants at this locus and disease
susceptibility (Moller et al. 1997; Malecki et al. 1998; Ghosh
et al. 1999; Price et al. 2000). This study differs from all other
previous reports in its examination of haplotypes, as well as
in the fact that it included several SNPs not previously
examined. Our ﬁndings lead us to speculate as to how a
particular HNF4A haplotype might be associated with lower
risk of diabetes and increased insulin secretory capacity. The
fact that a multiplicity of heterozygous nonsense and
missense mutations in HNF4a lead to an insulinopaenic form
of MODY strongly suggests that b-cell dysfunction is sensitive
to the amount of HNF4a in the b-cell and that haploinsufﬁ-
ciency is the likely mode of molecular pathogenesis in that
condition (Stoffel and Duncan 1997; Shih et al. 2000). It is
plausible, therefore, that variants in this gene that enhance
expression levels of the protein might lead to increased
insulin secretory capacity and protection against diabetes.
INS (encoding insulin). The INS (LocusLink ID 3630) gene
encodes the hormone preproinsulin, which upon proteolytic
cleavage generates mature insulin and C-peptide. We tested
for association of a single SNP in the 39-UTR (SNP72) of the
insulin gene with disease status. This SNP was signiﬁcantly
associated with increased Type 2 diabetes risk under a
recessive model for the T allele (OR 2.02, p ¼ 0.0258) (see
Table 2). In the QT study this SNP did not associate with any
of the intermediate phenotypes studied. The insulin gene
variable number tandem repeat (INS–VNTR) has been
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effects on birth weight and diabetes susceptibility (Huxtable
et al. 2000). However, evidence for this has been conﬂicting
and a role for INS in Type 2 diabetes predisposition has not
been deﬁnitively established. The data for the single SNP we
tested suggest that either the insulin gene or other loci in LD
may be involved in Type 2 diabetes risk.
Genes Primarily Affecting Insulin Action
INSR (encoding the insulin receptor). At the INSR locus of
the seven SNPs genotyped, we detected a single intronic SNP
(SNP131) that was signiﬁcantly associated with increased
disease risk (OR 1.48, p ¼ 0.0039 for the dominant model for
allele 2) (see Table 2). In the QT study, this SNP also had a
nonsigniﬁcant association with increased 2-h glucose under a
dominant model for allele 2 (see Table S2). Haplotype C (see
Figure 3C) for INSR was associated with increased disease risk
(1.34 mmol/l, 95% CI [1.05, 1.71]; data not shown); in the QT
study, there was a nonsigniﬁcant trend for subjects carrying
this haplotype to have increased values for fasting glucose
(5.32 mmol/l, 95% CI [5.24, 5.39] versus 5.27 mmol/l, 95% CI
[5.21,5.33] for haplotype B and 5.27 mmol/l, 95% CI [5.23,
5.32] for haplotype A), 2-h glucose (6.00 mmol/l, 95% CI [5.80,
6. 20] versus 5.78 mmol/l, 95% CI [5.61, 5.96] for haplotype B
and 5.87 mmol/l, 95% CI [5.75, 5.99] for haplotype A), and
fasting insulin (41.8 pmol/l, 95% CI [39.2, 44.5] versus 40.4
pmol/l, 95% CI [38.4, 42.5] for haplotype B and 41.3 pmol/l,
95% CI [39.6, 43.1] for haplotype A) (see Table 3). A role for
INSR in Type 2 diabetes and related phenotypes has long
been sought. Many studies initiated over the past decade have
explored the possibility that DNA variants at this locus would
not only cause rare syndromes of extreme insulin resistance,
but would also associate with increased Type 2 diabetes risk.
In particular, the role of the Val985Met in disease predis-
position has been analysed in many different populations, but
the data remain inconclusive, with some studies suggesting a
role for this variant (Hart et al. 1996, 1999b), while others do
not support this ﬁnding (O’Rahilly et al. 1991, 1992; L.
Hansen et al. 1997). In this study we provide preliminary
evidence for a role of INSR in diabetes susceptibility through
genotyping of a previously untested SNP in case-control
studies and via haplotype analysis using multiple SNPs in the
gene.
PIK3R1 and SOS1. The gene PIK3R1, encoding the p85a
regulatory subunit of the phosphatidylinositol 3-kinase, is a
logical candidate gene for involvement in the development of
Type 2 diabetes owing to its role in insulin signal trans-
duction. An intronic variant, SNP42, was associated with
increased disease risk under two genetic models (OR 1.41, p¼
0.0090 for the allele 2 dominant and OR1.34, p ¼ 0.0088 for
the additive model; see Table 2). In the QT study, SNP42 was
signiﬁcantly associated with increased BMI and showed a
borderline signiﬁcance with increased fasting insulin (meas-
ure of insulin resistance) under a dominant model for allele 2
(see Table S2). Obesity is a major risk factor for insulin
resistance, and the observed increase in BMI coupled with
increased insulin resistance in carriers of allele G at SNP42
suggests that variation at this gene may be increasing Type 2
diabetes risk through impaired insulin action. Other associ-
ation studies at this locus have focussed on investigating the
Met326Ile variant in disease predisposition, with mostly
negative results (T. Hansen et al. 1997, 2001; Kawanishi et
al. 1997). One study did describe an association with disease
status and with QTs underlying Type 2 diabetes (Baier et al.
1998). However, functional data for this polymorphism have
suggested that the Ile326 variant may have only minor impact
on signalling events (Baynes et al. 2000; Almind et al. 2002).
Our data suggest that variation in this gene is a risk factor for
the development of Type 2 diabetes, although further
detailed studies will be required to elucidate the precise
functional variants and mechanisms that lead to increased
disease risk.
The gene SOS1 (son of sevenless homolog 1 in Drosophila)
encodes a guanine nucleotide exchange factor that functions
in the transduction of signals that control cell growth and
differentiation. We analysed two SNPs for association with
disease status, a nonsynonymous SNP (N1011S) and an
intronic variant (SNP8). While the nonsynonymous S1011
variant, which was very rare (minor allele, 0.003), did not
associate with disease status, the intronic SNP was highly
signiﬁcantly associated with decreased disease risk (OR 0.58, p
¼0.0032) (see Table 2), despite not showing any effects in the
QT study. To our knowledge, this is the ﬁrst investigation into
the role of SOS1 in Type 2 diabetes risk. The data presented
here suggest that further investigation into the potential role
of common variants at this gene and diabetes risk is
warranted.
Other Genes
PPARGC1 (LocusLink ID 10891) encodes a transcriptional
coactivator of nuclear receptors with a critical role in
regulating multiple aspects of energy metabolism, including
adaptive thermogenesis (Puigserver et al. 1998), mitochon-
drial biogenesis (Wu et al. 1999), fatty acid b-oxidation (Vega
et al. 2000), the control of hepatic gluconeogenesis (Herzig et
al. 2001; Yoon et al. 2001), and the control of glucose uptake
(Michael et al. 2001). PPARGC1 SNP30 (Thr528Thr), which
was associated with decreased disease risk (see Table 2), was
rather surprisingly associated with decreased insulin secre-
tion in the QT study (see Table S2). In this locus, Thr528Thr
has not been previously associated with diabetes, and our
data most likely reﬂect stochastic variation at this site. The
Gly482Ser has in some studies been shown to be associated
with increased Type 2 diabetes risk (Ek et al. 2001), but not in
others (Hara et al. 2002; Lacquemant et al. 2002; Muller et al.
2003), and has additionally been associated with insulin
resistance (Hara et al. 2002), obesity indices in women
(Esterbauer et al. 2002), and mean insulin secretory response
and lipid oxidation (Muller et al. 2003). In our study, this
allele was not associated with increased diabetes risk, but
rather was associated with a lower risk of diabetes under a
recessive model (OR 0.67, p ¼ 0.0295) (see Table 2). The
opposing results for this polymorphism and the fact that the
amino acid change Gly482Ser is unlikely to be a major
functional change (Esterbauer et al. 2002) may indicate that
the contributing functional polymorphism may be an
unidentiﬁed variant in LD with the Gly482Ser.
Amongst the remaining genes tested, of particular interest
are the results observed in PYY (encoding polypeptide YY;
LocusLink ID 5697). An intronic variant, IVS3þ68, showed a
signiﬁcant association with increased Type 2 diabetes risk
under two genetic models (OR 1.47, p ¼ 0.0240 in the allele 2
dominant; OR 1.47, p ¼ 0.0157 in the additive effect allele 2)
(see Table 2), but no evidence of association with underlying
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suggested an inhibitory role of PYY in glucose-stimulated
insulin secretion (Bertrand et al. 1992; Nieuwenhuizen et al.
1994), which led us to evaluate the potential role of variants at
this gene in Type 2 diabetes predisposition. Recent data have
shown that the peptide PYY3–36 encoded by this gene inhibits
food intake and reduces weight gain when injected in rats,
while physiological infusions of PYY3–36 in humans decreased
food intake by 33% (Batterham et al. 2002). Although our
data do not show an association between the intronic variant
SNP122 with BMI, they suggest a putative role for PYY in
Type 2 diabetes predisposition. As we only tested a non-
coding variant in PYY, it is possible that the association is due
to other contributing variants within the gene and that a link
between those and BMI is still plausible.
In the genes ABCC9 (LocusLink ID 10060) and LIPC
(LocusLink ID 3990), single SNPs of modest signiﬁcance were
associated with disease status in the case control and
therefore are not discussed further here.
Examination of Other Previously Reported Associations
We were unable to conﬁrm some associations observed in
other studies. The PPARG Pro12Ala Pro allele has previously
been shown to confer susceptibility to Type 2 diabetes, with
the Ala allele providing a decreased risk (Altshuler et al.
2000). Our results for this polymorphism show the same
direction and magnitude of effect for Ala/Ala versus Ala/Pro
and Pro/Pro genotypes (OR 0.54; derived from data in Table
2), but the association was not statistically signiﬁcant (p ¼
0.2269). The lower limit of the 95% CI for the protective
effect of the Ala allele (OR 1.08, 95% CI [0.82,1.42], p¼0.583)
is still consistent with the results of the meta-analysis by
Altshuler et al. (2000). Our study was not sufﬁciently powered
to detect the small effects expected for the predisposing Pro
allele. The study only had 25.4% power to detect an OR of
1.25 for the Pro allele that occurred in 89.4% of our control
population. It is also possible that the Pro12Ala variant does
not affect diabetes susceptibility in this population, because
of the dependence of the allele effect on environmental
factors such as dietary fat composition (Luan et al. 2001).
In the ENPP1 (LocusLink ID 5167) gene (commonly known
as PC-1) the K121Q polymorphism has variably been found to
be both associated with increased Type 2 diabetes risk (Gu et
al. 2000; Rasmussen et al. 2000; Hegele et al. 2001) and with
insulin resistance QTs (Pizzuti et al. 1999; Gu et al. 2000;
Rasmussen et al. 2000). In our study we did not ﬁnd evidence
for association between the K121Q polymorphism and Type 2
diabetes (OR 1.10, p ¼ 0.5277 for the dominant model for
allele 2; OR 1.07, p¼0.6290 for the additive effect for allele 2;
OR 0.86, p ¼ 0.7496 for a recessive model for allele 2; data
derived from Table 2). Analysis of this allele in our QT study
showed that QQ individuals have higher mean BMI levels
compared to carriers of the K121 allele (28.3 kg/m
2 [26.4, 30.2]
versus 26.1 [25.6, 26.7] in KQ subjects, 26.3 [25.9, 26.6] in KK
subjects; data not shown). PPP1R3A (protein phosphatase 1
regulatory subunit 3; LocusLink ID 5506), which encodes the
muscle-speciﬁc regulatory subunit of PP1, has been inves-
tigated as a potential diabetogene. Evidence for a role of the
PPP1R3A D905Y polymorphism in Type 2 diabetes risk has
also been conﬂicting (L. Hansen et al. 1995, 2000; Hegele et al.
1998; Xia et al. 1998). While in this study we did not ﬁnd an
association between the D905Y variant and disease risk, we
have previously described an association between a rare
frameshift and premature stop variant with Type 2 diabetes
risk under a dominant model (OR 5.03, p ¼ 0.0110) in this
population (Savage et al. 2002).
Concluding Remarks
This study, which to our knowledge is the largest of its kind
yet reported in Type 2 diabetes, has provided evidence for
the existence of variants in certain key candidate genes that
inﬂuence the risk of Type 2 diabetes and, in some cases, has
afforded clues as to the pathophysiological mechanism
whereby those effects on disease risk might be mediated. By
its very nature, any study of candidate genes, however large, is
restricted in scope, and it is likely that other variants (namely
in regulatory regions, which we did not cover) in the genes
that we have considered, as well as ones that we have not, may
exist and have effects equal to or greater than those we have
demonstrated. In addition, this study is not intended to be an
‘exclusion study,’ as many issues that relate to coverage of any
given gene, environmental risk factors, and power in our
populations do not allow us to deﬁnitively assert that negative
ﬁndings correspond to genes that truly do not play a role in
Type 2 diabetes predisposition.
The power of our study to detect small effects in
uncommon variants was low. Evidence from many recent
studies now suggests that in Type 2 diabetes the effects are
likely in the range of OR 1.15–1.5. It is clear that much larger
studies than that reported here are required for such effects
(Figure 4), in particular when adjusting to a lower Type 1
error rate of 0.01% to compensate for multiple testing. The
signiﬁcance of the associations we report have been described
without adjustment for the number of tests undertaken, and
thus the group of positive associations is likely to contain a
proportion that is falsely positive. There is no consensus
about the ideal method for adjusting the probability of an
observation occurring by chance for multiple testing. The
simple Bonferroni correction would constitute overadjust-
ment because the 152 genetic markers in this study are not
independent. In addition, in the false-discovery rate method
(Benjamini and Hochberg 1995), it is assumed that all N tests
are carried out simultaneously, which may not correspond to
reality if groups genotype one set of SNPs, as in this study, but
then report results for additional SNPs at a later date. It is not
clear whether the number of tests N should reﬂect the
number to date or the number one might potentially
undertake by continuing working through projects like these.
An alternative Bayesian approach leading to a ‘genome-wide’
signiﬁcance level for association, such as has been done for
whole-genome linkage studies (Lander and Kruglyak 1995),
might be preferable. However, this also runs into difﬁculties.
In studies that are not based on ﬁne-mapping of linkage
intervals, but rather on candidate genes selected on the basis
of data from other studies, including previous reports of
association, it is unclear what level of prior probability of
association should be used. As a result of this uncertainty
about the appropriate method of correction for multiple
testing, our preferred strategy is to report the number of tests
done and to encourage readers to interpret the signiﬁcance
tests in that light, acknowledging that the results will require
replication in other cohorts.
Although we have not undertaken a formal replication of
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population to examine the association of the variants studied
with continuously distributed measures of glucose tolerance,
insulin secretion, and insulin action. This provides different
information to a replication case-control study, as it may
identify pathophysiological mechanisms by which the associ-
ation with diabetes arises. We are cautious about putting
forward particular variants as established ‘diabetogenes’ and
enthusiastically invite researchers to examine these candidate
variants in their own particular populations. Indeed, as the
genetic architecture of Type 2 diabetes may vary between
populations, it is critical that such variants are examined in
multiple diverse ethnic groups. As with the Pro12Ala PPARG
example, it is likely that meta-analysis of several studies will
be required to narrow the CIs around the point estimates of
association seen in any single study. This will be especially
important when the association is weak, as it is for Pro12Ala,
because few individual case-control studies, including the one
reported here, are currently powered to detect very small
increases in risk. It is, however, important that such meta-
analyses include all studies of variants examined, rather than
only those that are individually published, to avoid publica-
tion bias.
The associations we describe are highly biologically
plausible and in many of the genes are supported by
associations with multiple SNPs at the same locus. These
include genes affecting both insulin secretion and insulin
action. Given the importance of both insulin resistance and
defective b-cell function to the pathogenesis of Type 2
diabetes, it is intriguing that we have found a dispropor-
tionate representation of genes affecting pancreatic b-cell
function among those that were found to be associated with
diabetes risk. This contrasts with the impact of known
environmental factors and their correlates (e.g., high-fat diet,
lower physical activity, obesity, and central fat distribution),
all of which are thought to have their major inﬂuence on
diabetes risk through impairment of insulin action. While it
would be premature to put forward any deﬁnitive model for
the causation of Type 2 diabetes, it is tempting to speculate
that the ‘insulin resistance’ component of the disease may
have a substantial environmental inﬂuence modulated by
polygenic effects, some of which may relate to molecules
identiﬁed in this and other studies. On the other hand, the
ability of the pancreatic b-cell to continue to secrete
sufﬁcient insulin to maintain life-long normoglycaemia may
be more profoundly inﬂuenced by genetic factors, some of
which are reported herein. It will be critical to examine the
functional consequences of such variants, a task that will be
particularly challenging when it comes to genes inﬂuencing
human b-cell function, as it is entirely possible that this
disproportionate representation of b-cell genes may be a
reﬂection of our success in choosing diabetes genes in each of
the candidate genes in the major groupings.
The success of the approach presented here, although
necessarily limited in scope, suggests that the systematic
examination of panels of biological candidate genes in large,
well-characterised populations may usefully complement
positional approaches to the identiﬁcation of allelic variants
conferring susceptibility to complex polygenic disease. The
detection of multiple small gene effects accentuates the need
for larger populations in order to reliably identify the types
of effects (OR 1.15–1.5) we now expect for complex diseases.
Materials and Methods
Methods for SNP discovery and SNP selection for genotyping. SNP
discovery was performed by a high-fSSCP-based analysis, as pre-
viously described (Thorpe et al. 1999). Genomic structure was
determined for all genes, and primers were designed to span the
exons and splice junctions. To detect common variants, genes were
screened against one or more of a variety of different DNA panels,
which included a 47-member multiethnic human diversity panel
(comprised of 17 Europid, seven Hispanic, 13 East Asian, and ten
African-American subjects), our 129-member severe insulin-resistant
cohort (Barroso et al. 1999), a panel of 47 European-American
samples, a panel of 47 African-American samples, and in some cases a
panel of 94 samples (half European and half Asian Indian). Some
genes had only partially screened coding sequence and splice
junctions at the time of SNP selection for genotyping. In addition,
we had access to an internal database of in silico SNPs that had been
validated against 100 samples. Choice of polymorphisms for further
testing in association studies was not constrained by the type of
variant (e.g., nonsynonymous, silent, noncoding), although higher
priority was given to variants with a likely effect on protein structure
and function. Polymorphisms with a minor allele frequency greater
than or equal to 5% were selected for further testing in population-
based studies. In some instances, polymorphisms of lower allele
frequency were genotyped to examine whether lower frequency
variants with high penetrance might account for some cases of
polygenic disease. Polymorphisms of lower frequency were also
genotyped when, at the time of selection for genotyping, no other
variants of known frequency were identiﬁed in the gene to test.
Populations for SNP genotyping. The Cambridgeshire Case-
Control Population (Poulton et al. 2002; Halsall et al. 2003) consists
of a collection of 517 Type 2 diabetics and 517 matched controls. The
cases were a random sample of Europid men and women with Type 2
diabetes, aged 47–75 years, from a population-based diabetes register
in a geographically deﬁned region in Cambridgeshire, United
Kingdom. The presence of Type 2 diabetes in these subjects was
deﬁned as onset of diabetes after the age of 30 years without use of
insulin therapy in the ﬁrst year after diagnosis. The control subjects
were individually age-, gender-, and geographical location-matched
to each of the cases. Controls were not matched by BMI to cases.
Potential controls that had HbA1c levels greater than 6% were
excluded, as this group may contain a higher proportion of
individuals with previously undiagnosed diabetics. HbA1c was assayed
using high performance liquid chromatography on a BioRad Diamat
33 (Hercules, California, United States), according to the method of
Standing and Taylor (1992). The coefﬁcient of variation (CV) was
3.6% at the lower end of the range (mean ¼ 4.94%) and 3.0% at the
upper end (mean ¼ 9.76%). Further details on the characteristics of
the subjects are shown in Table 5.
The QT study population is a collection of 1,100 samples collected
for the Ely Study, a prospective population-based cohort study of the
aetiology and pathogenesis of Type 2 diabetes and related metabolic
Figure 4. Size of Case-Control Study Required to Detect Small Risk
Effects
The number is shown of the case chromosomes (assuming an equal
number of control chromosomes) required to attain 80% power to
detect associations with the OR varying between 1.0 and 1.5 and with
a Type 1 error rate of 0.01%. Abbreviations: p0, frequency of the
predisposing allele; chr, number of chromosomes. Graphs were
plotted with the PS power and sample-size program (DuPont and
Plummer 1997).
DOI: 10.1371/journal.pbio.0000020.g004
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stadiometer, and weight was measured on Seca-calibrated scales with
participants in light clothing. BMI was estimated as weight (kg)
divided by height (m) squared. Plasma glucose was measured in the
routine National Health Service Laboratory at Addenbrooke’s
Hospital, using the hexokinase method (Kunst et al. 1983). Plasma
insulin was measured by two-site immunometric assays with either
125I or alkaline phosphatase labels (Sobey et al. 1989; Alpha et al.
1992). Cross-reactivity with intact proinsulin was less than 0.2% and
CVs were less than 7%.
Methods for genotyping. Genotyping was performed using an
adaptation of the ﬂuorescence polarisation template-directed incor-
poration (FP-TDI) method described by Chen et al.(1999). In short,
PEP-ampliﬁed DNA samples were PCR-ampliﬁed in 8 ll reactions
with primers ﬂanking the variant site; unincorporated dNTP and
remaining unused primer were degraded by exonuclease I and
shrimp alkaline phosphatase at 378C for 45 min before the enzymes
were heat-inactivated at 958C for 15 min. At the end of the reaction,
the samples were held at 48C. Single base primer extension reactions
were performed as previously described (Chen et al. 1999), and allele
detection was performed by measuring ﬂuorescence polarisation on
an LJL Analyst ﬂuorescent reader (Molecular Devices, Sunnyvale,
California, United States). The PEP protocol was speciﬁcally
developed and tested to ensure that allele bias was not introduced
during the ampliﬁcation process. A minimum of 12% internal
replicate samples within each population (case control and QT) were
included in all genotyping tests to assess genotyping accuracy. Only
assays that provided 100% concordance between replicates were
analysed for association. The genotyping pass rate was greater than
90% once a working assay had been established. There was an 85%
success rate for an SNP to be converted into a working assay at the
ﬁrst attempt, with a number of failed assays recovered by designing
an assay to the reverse strand.
Statistical analysis. All analyses used SAS 8.02 (SAS Institute, Cary,
North Carolina, United States) or Stata 7.0 (Stata Corporation,
College Station, Texas, United States) statistical programs, unless
otherwise stated. Agreement with Hardy–Weinberg equilibrium was
tested using a v
2 ‘goodness-of-ﬁt’ test. The disequilibrium coefﬁcient
for the controls (r
2) was calculated (Lewontin 1964).
For the case-control study, tests for association with disease status
under dominant, additive, and recessive models were undertaken
using univariate logistic regression analysis. Dominance was deﬁned
in terms of allele 2 effects; in the dominant allele 2 model,
homozygous subjects for allele 1 were compared with carriers of
allele 2; in the recessive allele 2 model, carriers of allele 1 were
compared with homozygous subjects for allele 2. In some cases, a
large number of polymorphisms within a gene were typed. To reduce
complexity, a subset of markers within a gene associated with
diabetes status was identiﬁed using backward logistic regression. Any
polymorphism that had a p value greater than 0.1 was removed from
the model. The genotypes were assumed as having additive effects. p
values for the additive effect are for the test for a linear trend across
the genotypes, which were coded as 0¼ 11, 1 ¼12, 2 ¼22. Where the
subset consisted of more than one polymorphism within a gene,
haplotype analysis was performed. To avoid possible errors due to
either genotyping or the estimation process, only haplotypes that had
a frequency greater than 5% were considered for further analysis.
Haplotype frequencies were estimated using maximum-likelihood
methods. A log-linear model embedded with the expectation-
maximization algorithm was ﬁtted to a frequency table (Chiano and
Clayton 1998; Mander 2001). Differences in haplotype distributions
between the diabetic and nondiabetic groups were examined using a
likelihood-ratio statistic (Mander 2001). To obtain separate ORs for
each haplotype, the most common haplotype was used as the
reference category. CIs were obtained using a proﬁle-likelihood
approach (Mander 2001).
For the QT study, the distributions of fasting plasma glucose, 2-h
plasma glucose, fasting plasma insulin, and insulin increment were
skewed and were thus normalised by logarithmic transformation.
Baseline and follow-up measurements of BMI, fasting and 2-h plasma
glucose, fasting plasma insulin, and 30-min insulin increment during
an oral glucose tolerance test were collected. Where two measures
were available, the mean was used. Otherwise, a single measure (either
baseline or follow-up) was used for further analysis. The subset of
SNPs identiﬁed in the case-control study was used. In separate
dominant, additive, and recessive models, adjusting for age and sex,
genotype differences in these measurements were modelled using the
General Linear Model procedure in the statistical package SAS. For
each individual, a list of possible haplotypes and their probabilities
was obtained using Snphap software (http://www-gene.cimr.cam.ac.uk/
clayton/software/). Haplotypes with a frequency greater than 5% were
the same as those reconstructed in the case-control study. Only
haplotypes that had a frequency greater than 5% and individuals that
had at least one marker typed were considered for analysis. As
currently haplotype analysis software cannot handle repeated
measurements, the average of two measurements was used for further
analysis. Associations of haplotypes (adjusted for age and sex) with
the QTs were determined by cluster-weighted regression analysis,
thereby taking into account nonindependent multiple observations
from an individual (Huber 1967; White 1980, 1982). QT means and
their 95% CI were estimated for each haplotype.
Supporting Information
Table S1. Genotype Counts and Frequencies for All SNPs Genotyped
in This Study
View online at DOI: 10.1371/journal.pbio.0000020.st001 (79 KB XLS).
Table S2. Single SNP Associations with QTs
View online at DOI: 10.1371/journal.pbio.0000020.st002 (174 KB
DOC).
Table 5. Study Subjects in the Cambridgeshire Case-Control Study
Men Women
Case
(n ¼ 331)
Control
(n ¼ 331)
p Value Case
(n ¼ 186)
Control
(n ¼ 186)
p Value
Age (years) 63.7 (0.4) 63.7 (0.4) 0.96 63.3 (0.6) 63.5 (0.6) 0.93
Age at
diagnosis
(years)
55.8 (0.5) — — 55.5 (0.7) — —
BMI (kg/m
2) 28.6 (0.2) 27.1 (0.2) ,0.0001 31.6 (0.5) 27.6 (0.4) ,0.0001
Number of
individuals in
treatment for
diabetes
92 (diet alone)
230 (tablets
or/and
insulin)
— — 45 (diet
alone) 137
(tablets
or/and
insulin)
——
Data are means and standard error is in parentheses.
DOI: 10.1371/journal.pbio.0000020.t005
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The LocusLink accession numbers discussed in this paper are 3170,
3172, 3630, 3643, 3767, 3990, 5167, 5295, 5468, 5506, 5697, 6514, 6654,
6833, 6927, 6928, 10060, 10891, and 11132.
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